Medtronic (NYSE:MDT) yesterday touted the results of meta-analyses of a group of company-sponsored studies of its cardiac resynchronization therapy devices, saying the data show the clinical and economic value its CRT portfolio.
In 1 study, a look at 5 randomized controlled trials (Care-HF, Miracle, Miracle-ICD, Raft and Reverse) involving 3,872 patients showed a 26% relative reduction in readmissions for CRT-treated patients among the 678 subjects hospitalized for heart failure. Patients with more advanced cases of heart failure showed a higher, 31% benefit than less acute patients, according to a press release.
A 2nd analysis of another 5 Medtronic studies (Miracle, Miracle-ICD, InSync III Marquis, Prospect and Adaptive CRT) involving 1,603 subjects showed that patients who either improved or were the same 6 months after CRT treatment were projected to live longer and consume fewer hospital resources than patients whose heart failure worsened, Medtronic said.
The data were presented at the annual American Heart Assn. meeting yesterday in Chicago.
“Medtronic is committed to bringing forward sound innovation that improves patients’ lives and provides economic value by reducing cost to the healthcare system," Dr. David Steinhaus, vice president & GM of Medtronic’s heart failure business and medical director of its cardiac rhythm & heart failure unit, said in prepared remarks. "Cardiac resynchronization therapy is an important tool in the management of heart failure and these data are a prime example of how innovations, including Medtronic’s AdaptivCRT pacing algorithm, can enhance the clinical and economic value of an already proven therapy."
"The efficient management of heart failure is a growing priority for healthcare," added Dr. Linda Gillam of New Jersey’s Atlantic Health System. "These new economic data reinforce the important benefits of CRT and demonstrate its value, not only for patient health, but also the fiscal health of the hospitals and health systems that treat them."